AG
LUMO

Artal Group’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Artal Group’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-16,667
Closed -$1.38M – 129
2017
Q3 		$1.53M Buy
+16,667
New +$1.28M 0.03% 99

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Artal Group's LUMO Position: Q4 2017 in Review

Artal Group sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2017, closing a stake of 16,667 shares — an estimated $1.38M sold.

Artal Group first reported a position in LUMO in Q3 2017 and held it in 1 quarter. The position peaked at $1.53M in Q3 2017. 130 funds tracked by Wall St. Rank hold LUMO as of Q4 2017.

  • Artal Group reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Artal Group sold 16,667 Lumos Pharma, Inc. Common Stock shares in Q4 2017, an estimated $1.38M.
  • Artal Group first reported a position in Lumos Pharma, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Artal Group's Lumos Pharma, Inc. Common Stock position peaked at $1.53M in Q3 2017.
  • 130 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2017.

Based on Artal Group's 13F filing for Q4 2017, filed 9 Feb 2018.